Claims of equivalence in medical research: Are they supported by the evidence?

Annals of Internal Medicine

Volumn 132, Issue 9, 2000, Pages 715-722

  Greene, William L ^a   Concato, John ^b   Feinstein, Alvan R ^b  

^a GENENTECH INC   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ARTICLE; CLINICAL STUDY; DEVICE; EVIDENCE BASED MEDICINE; INTERMETHOD COMPARISON; MEDICAL RESEARCH; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STOCHASTIC MODEL;

EID: 0034595229     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-9-200005020-00006     Document Type: Article

References (41)

1. Dong BJ, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL, et al. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA. 1997;277:1205-13.
2. Oles KS, Penry JK, Smith LD, Anderson RL, Dean JC, Riela AR. Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology. 1992;42:1147-53.
3. Oberlin O, Leverger G, Pacquement H, Raquin MA, Chompret A, Habrand JL, et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol. 1992;10:1602-8.
4. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996; 88:890-9.
5. Taggart SC, Custovic A, Richards DH, Woodcock A. GR106642X: a new, non-ozone depleting propellant for inhalers. BMJ. 1995;310:1639-40.
6. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995;311:485.
7. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996;313:36-9.
8. Spriet A, Beiler D. When can 'non significantly different' treatments be considered as 'equivalent'? Br J Clin Pharmacol. 1979;7:623-4.
9. Kron IL, Kern JA, Theodore P, Flanagan TL, Haines DE, Barber MJ, et al. Does a posterior aneurysm increase the risk of endocardial resection? Ann Thorac Surg. 1992;54:617-20.
10. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996;124:717-25.
11. Stock AJ, Kofoed L. Therapeutic interchange of fluoxetine and sertraline: experience in the clinical setting. Am J Hosp Pharm. 1994;51:2279-81.
12. Edgar PP, Schwartz RD. Functionally relevant gamma-aminobutyric acid A receptors: equivalence between receptor affinity (Kd) and potency (EC50)? Mol Pharmacol. 1992;41:1124-9.
13. Palazzini M, Cristofori M, Babbini M. Bioavailability of a new controlled-release oral naproxen formulation given with and without food. Int J Clin Pharmacol Res. 1992;12:179-84.
14. Mason KA, Thames HD, Ochran TG, Ruifrok AC, Janjan N. Comparison of continuous and pulsed low dose rate brachytherapy: biological equivalence in vivo. Int J Radiat Oncol Biol Phys. 1994;28:667-71.
15. Cohen J. Statistical Power Analysis in the Behavioral Sciences. 2d ed. Hillsdale, NJ Erlbaum; 1988.
16. Ware JH, Antman EM. Equivalence trials [Editorial]. N Engl J Med. 1997; 337:1159-61.
17. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27:S178-S189.
18. Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. N Engl J Med. 1978;299:690-4.
19. National Library of Medicine Abridged Index Medicus. v 28. Washington, DC: U.S. Department of Health and Human Services; 1997.
20. Rammeloo RH, Luursema PB, Sips AP, Beumer HM, Wald FD, Cornelissen PJ. Therapeutic equivalence of a fenoterol/ipratropium bromide combination (Berodual) inhaled as a dry powder and by metered dose inhaler in chronic obstructive airway disease. Respiration. 1992;59:322-6.
21. Jurgens RW, Downey LJ, Abernethy WD, Cutler NR, Conrad J. A comparison of circulating hormone levels in postmenopausal women receiving hormone replacement therapy. Am J Obstet Gynecol. 1992;167:459-60.
22. Barckow D, Schwigon CD. Cefepime versus cefotaxime in the treatment of lower respiratory tract infections. J Antimicrob Chemother. 1993;32:187-93.
23. Di Munno O, Imbimbo B, Mazzantini M, Milani S, Occhipinti G, Pasero G. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. J Rheumatol. 1995;22:1492-8.
24. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolisnn in medical inpatients. Haemostasis. 1996;26:127-39.
25. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction: trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet. 1995;346:329-36.
26. Boissel JP, Collet JP, Lion L, Ducruet T, Moleur P, Luciani J, et al. A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice. The OCAPI Study Group Optimiser le Choix d'un Anti-hypertenseur de Premiere Intention. J Hypertens. 1995;13:1059-67.
27. Groothuis JR, Simoes EA, Lehr MV, Kramer AA, Hemming VG, Rodriguez WJ, et al. Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin. Antimicrob Agents Chemother. 1995;39:668-71.
28. Dunnett CW, Gent M. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2×2 tables. Biometrics. 1977;33:593-602.
29. Feinstein AR. Clinical biostatistics. XXXIV. The other side of "statistical significance": alpha, beta, delta, and the calculation of sample size. Clin Pharmacol Ther. 1975;18:491-505.
30. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep. 1978;62:1037-40.
31. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15:657-80.
32. Fuller RW, Hallett C, Dahl R. Assessing equivalence of inhaled drugs. Respir Med. 1995;89:525-7.
33. Lecoutre B, Derzko G, Grouin JM. Bayesian predictive approach for inference about proportions. Stat Med. 1995;14:1057-63.
34. O'Quigley J, Baudoin C. General approaches to the problem of bioequivalence. The Statistician. 1988;37:51-8.
35. Feinstein AR. Zeta and delta: critical descriptive boundaries in statistical analysis. J Clin Epidemiol. 1998;51:527-30.
36. Kragh-Sorensen P, Muller B, Andersen JV, Buch D, Stage KB. Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study. J Clin Psychopharmacol. 1995;15:24S-30S.
37. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993; 329:673-82.
38. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. The Continuous Infusion versus double-bolus administration of Alteplase (COBALT) Investigators. N Engl J Med. 1997;337:1124-30.
39. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet. 1999; 354:716-22.
40. Verster GC, Joubert G, Stevens M, van der Merwe H. Generic substitution - comparing the clinical efficacy of a generic substitute for fluphenazine decanoate with the original product. S Afr Med J. 1998;88:260-2
41. Babul N, Provencher L, Laberge F, Harsanyi Z, Moulin D. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. J Clin Pharmacol. 1998;38:74-81.